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Background: Proton magnetic resonance spectroscopy provides a non-invasive technology to study brain
metabolite levels in vivo, which can be used to measure biochemical compounds or metabolite concentrations in
circumscribed brain regions. Previous research has highlighted the role of glial cells in brain white matter. It has
been assumed that antidepressant treatment with SSRIs not only affects neurons, but also activates glial cells. This
study focused on the observation of any potential changes in the metabolite levels of the ventral prefrontal white
matter in major depressive disorder (MDD) patients who have received antidepressant treatment.
Methods: 17 female patients diagnosed as MDD according to Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria with the scores of 18 and above on the 24-item Hamilton Depression
Rating Scale (HDRS) were recruited. MRS studies were performed on a 3.0 T MR system, single voxel PRESS
spectroscopy with chemical-shift selective saturation water suppression. The volume of interest was localized at
the bilateral ventral prefrontal white matter regions (voxel size: 2 × 2 × 2 mm3). The spectral data analysis was
performed by using the instrument manufacturer supplied software.
Results: The bilateral ventral prefrontal white matter of MDD patients showed significantly lower Cho/Cr (p < 0.05)
before receiving treatment. The HDRS, as the indicator of treatment response, showed a significant decrease in
patients who had gone through 12 weeks treatment (p < 0.01). The bilateral Cho/Cr values of post-treatment
patients were increased significantly compared to that of pre-treatment (p < 0.05).
Conclusion: The alteration of ventral prefrontal white matter metabolite levels are likely involved in MDD
pathophysiology and imply a crucial role of white matter in MDD.
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Major depressive disorder (MDD) is a highly prevalent
psychiatric disorder. Major symptoms of this disease are
characterized by persistent feelings of depressed mood,
loss of motivation, feelings of worthlessness and suicidal
tendencies. The understanding of the nature and causes of
depression has evolved over the centuries, although this
understanding is incomplete and has left many aspects of* Correspondence: liliqin_1999@yahoo.com; nwu@se.edu
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Proposed causes include psychological, psychosocial,
hereditary, evolutionary and biological factors [1]. Al-
though brain abnormalities have been found in MDD
patients by numerous neuroimaging studies, the precise
pathophysiological mechanisms of depressive disorder
are still not clear.
The main method for antidepressant treatment is
pharmacological. Selective serotonin reuptake inhibitors
(SSRIs) are widely used in the treatment of depression.
The diagnosis of MDD is mainly based on clinical signs
and symptoms, and treatment protocols are established
based on clinical empirical evidence [2,3]. Exploration ofticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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MDD such as proton magnetic resonance spectroscopy
has the potential to predict the response to treatment in
patients with MDD.
Proton magnetic resonance spectroscopy (1H-MRS) is
a non-invasive MRI technique that can quantify the con-
centration of multiple metabolites, including N-acetyl-
aspartate (NAA), choline (Cho), and creatine (Cr). NAA
is generally known as a marker of neuronal density and
viability, as lower concentrations of this metabolite are
thought to be indicative of loss of neural function [4,5].
Cho is a considered to be the marker of membrane integ-
rity and altered levels of this molecule are also associated
with neurobiological diseases. Cr reflects ATP metabolism
and production and is relatively constant across the brain.
It is generally used as a reference metabolite to which
other metabolites are normalized to [6,7].
Reviews and meta-analyses analysis of the 1H-MRS
literature on major depression found evidence that abnor-
malities in the hippocampus, basal ganglia and prefrontal
lobes were present. Evidence indicates a correlation be-
tween changes in neuro-metabolite concentrations, in par-
ticular glutamate, NAA, GABA and choline, with a positive
treatment response to pharmacotherapy or antidepressant
stimulation techniques [8]. In earlier MRS studies of MDD,
Sonawalla et al. found that Cho/Cr ratios increased after
8 weeks of fluoxetine treatment in the basal ganglia [9].
Gonul et al. found decreased NAA/Cr ratios in depressive
patients and these levels in the left medial frontal cortex
may increase significantly after treatment with SSRIs [10].
Alternatively, there are also MRS studies in depression
that reported positive treatment responses to sleep
deprivation (SD), electroconvulsive therapy (ECT), or
repetitive transcranial magnetic stimulation (rTMS) in
the DLPFC, amygdala, pontine, hippocampus, and the
occipital cortex [11-16]. However, up until now, evi-
dence for the effects of antidepressive treatment with
SSRIs on frontal white matter regions in humans has
rarely been reported.
The prefrontal areas play an important role in mood
regulation. This includes the ventral prefrontal lobe in-
cluding the medial PFC, orbitofrontal cortex, subgenual
PFC, a part of ACC, and white matter structures. Proper
function of these regions is involved in the coupling of
thoughts, memories, and experience with corresponding
emotional and visceral states. These regions are often re-
ferred to as “paralimbic” regions and play an important
role in linking cognition with visceral states and emotion
[17,18]. The prefrontal lobe cortex can pass the neural
signals to the limbic system including the regions of
cingulate gyrus, amygdala, etc. through the white matter
neural fibers, which composes the MDD neural emotional
signal transduction pathway. Therefore, the ventral pre-
frontal white matter is the major transduction pathwaythat connects the cortex of the prefrontal lobe and the re-
gions of limbic system. Earlier studies of SSRIs focused on
neuron and neurotransmission systems and seldom do
these articles address to the role of white matter [19].
A recent study however has highlighted the role of
glial cells in the brain frontal white matter. It had been
assumed that antidepressant treatment not only affects
neurons, but also activates glial cells [20]. Previous arti-
cles on MDD indicate that studies using Structural MRI,
fMRI, diffusion tensor imaging (DTI) and Postmortem
show abnormalities or impairments in ventral prefrontal
white matter [21-24]. These studies may suggest that pre-
frontal white matter plays an important role in the patho-
physiology of MDD. Therefore, the purpose of our study
was to observe the biochemical alterations in ventral pre-
frontal white matter and examine whether there was any
effect of antidepressant treatment on the metabolite levels
in this area in the depressed patients.
Methods
Subjects
The protocol was approved by the ethics committee of
the Beijing Friendship Hospital and the studies were car-
ried out in strict accordance with the Declaration of
Helsinki. All participants were female and right-handed.
17 patients (mean age 43 ± 10 years) diagnosed as MDD
according to Structured Clinical Interview for the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV), with scores of 18 or greater on the 24-
item Hamilton Depression Rating Scale (HDRS) were
recruited for the study group. In addition, 19 healthy vol-
unteers (mean age 41 ± 10 years) were recruited as normal
control. All normal subjects were carefully screened by a
diagnostic interview, a Structured Clinical Interview for
DSM-IV Non-patient Edition, to rule out the presence of
current or past psychiatric illness. All participants signed
an “Informed Consent” form after receiving a complete
description of the study. All patients had not taken any
antidepressants for at least 8 weeks prior to the examin-
ation and had the duration of illness over 24 months. The
following exclusion criteria was applied to all participants:
(1) the presence of other psychiatric disorders and
symptoms, (2) a history of treatment with any psycho-
tropic medication, psychotherapy or electroconvulsive
therapy, (3) a history of neurological or organic brain
disorder, (4) alcohol/substance abuse within 6 months
before study entry, (5) any physical illness demonstrated
by personal history, or clinical or laboratory examina-
tions, and (6) first-degree relatives showing a history of
neurological or mental illness.
MRS scanning procedure
MRS scanning was performed on both control and pa-
tient groups before SSRIs treatment. The patient group
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applying SSRIs treatment (Paroxetine, 20 mg/d). Depression
severity at follow-up was also evaluated by using the HDRS.
MRS studies were performed on a 3.0 T MR system
(General Electric, Excite Signa HD 3.0 T). A standard
eight-channel head coil was used for radio frequency
transmission and reception of the MR signal. Magnetic
resonance imaging examination protocol included three
dimensional fast-spoiled gradient-echo (3D-FSPGR) se-
quence [repetition time (TR)/echo-time (TE) = 6/2.5 ms,
slice thickness: 1 mm, number of slices: 160, interslice
gap: 0 mm, field of view (FOV): 220 × 220, number of
excitation (NEX) = 1] that were obtained to confirm the
absence of any structural and signal abnormality of the
brain. Single voxel PRESS (spin-echo point resolved)
spectroscopy (TR/TE: 1500/35 ms, voxel size: 2 × 2 ×
2 mm3, field of view: 24 × 24,number of excitation = 8)
with chemical-shift selective saturation (CHESS) water
suppression was used for 1H MR Spectra measurements.
The volume of interest (VOI) was localized at the bilat-
eral ventral prefrontal white matter regions. According
to the mechanical requirements of GE 3.0 T MR system,
the area of VOI was set as 2 × 2 × 2 = 8 cm3. The VOI
boarders were determined by avoiding any potential
cerebral spinal fluid area and including as much as pos-
sible of the white matter tissue regions. Figure 1 shows
the VOI location in brain MRI scanning. During voxel
placement, avoiding the adjacent grey matter containing
some part of the prefrontal was not achieved because of
the voxel size. Total acquisition time for 1H MRS se-
quence was 4 min and 36 s. The analysis of the spectral
data was performed with the MRI manufacturer-supplied
software (GE Advantage Workstation: AW4.2). The values
of the NAA/Cr, Cho/Cr ratios were automatically analyzed
by the MR system. Voxel placements for spectroscopy and
all data analysis was carried out by a trained radiologist
who was blind to each subject’s diagnosis.
Statistical analysis
All data analysis was performed by using SPSS for Win-
dows software, version 13.0 (SPSS Inc. Chicago, IL,Figure 1 Sagittal, coronal and axial scout MR images showing an 8-cm3 vo
prefrontal lobe.USA) and two-tailed significance level was set at 0.05.
Independent sample t-test was used to compare demo-
graphic data between the MDD and healthy control
groups at pre-treatment condition. To assess treatment
response, Hamilton Depression Scale and 1H-MRS mea-
sures were compared between pre-treatment and post-
treatment of patients by paired t tests. Data was pre-
sented as means and standard deviations.
Results
The clinical symptoms of all participating patients were
significantly improved after the completion of the SSRI
treatment course. Both HAM-A and HAM-D scores of
each individual patient showed significant reduction after
the SSRI treatment compared to that before the treatment
(data not shown).
Pre-treatment MRS comparison
The pre-treatment comparison study between MDD pa-
tients and normal control groups revealed that there was
significantly lower Cho/Cr in bilateral ventral prefrontal
white matter of MDD patients than in the normal con-
trol group (both left and right sides: p < 0.05). However,
there was no significant difference on NAA/Cr levels in
bilateral ventral prefrontal white matter between the two
groups. Table 1 summarizes the results of Independent
sample t-tests with mean value (SD) for relative metab-
olite concentrations in the bilateral ventral prefrontal
white matter volume of interest.
Post-treatment MRS comparison
After applying SSRI treatment (Paroxetine, 20 mg/d) for
12 weeks, the HDRS had significantly decreased in MDD
patients (p < 0.01), which indicated a positive response to
the treatment. All patients’ second MRS exam results
demonstrated significant increases of bilateral Cho/Cr
values compared to the same patient’s pre-treatment value
(Figure 2). Paired sample t-test results showed that there
was significant difference between the pre- and post-
treatment in bilateral ventral prefrontal white matter of
the same patient (left side: p < 0.01; right side: p < 0.05)xel predominantly centered white matter of the bilateral ventral






NAA/Cr Cho/Cr NAA/Cr Cho/Cr
Patient (n = 17) 1.51 (0.17) 0.99 (0.09) 1.61 (0.16) 0.97 (0.11)
Controls (n = 19) 1.59 (0.15) 1.08 (0.11) 1.63 (0.13) 1.10 (0.15)
t value 0.91 2.45 0.31 2.53
P value 0.31 0.03 0.20 0.04
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on NAA/Cr level in bilateral ventral prefrontal white mat-
ter after treatment. Results of metabolite ratio comparison
are summarized in Table 3.
Discussion
To our knowledge, this is the first study using MRS to
detect a drug response in the bilateral ventral prefrontal
white matter in patients with MDD.
Two major metabolite ratios (NAA/Cr and Cho/CR)
were evaluated in this study through comparative ana-
lysis of patient/control pre-treatment MRS data and the
same patient pre-/post- treatment MRS results. There
were no significant differences found on NAA/Cr level
in both pre- and post-treatment results. The NAA func-
tions in the brain as an acetyl donor for acetyl coenzyme
A and has been implicated in several neuronal processes,
including lipid and protein synthesis, mitochondrial
functioning, and osmoregulation [25,26]. NAA is com-
monly considered to be a marker of neuronal and axonal
integrity [27,28]. Thus, reduction in NAA concentration
possibly reflects the loss of neural function. Our results
indicated that the NAA levels showed no differenceFigure 2 Comparison of the same patient’s pre- (left) and post- (right) treabetween the patient and control groups. A possible ex-
planation for such results is due to the restricted selec-
tion of VOI used in this study. The selected area was
mainly focused on prefrontal white matter in which glial
cells accounted for the majority while the primary site
for NAA synthesis is in the neurons of the cortex [25].
The results did show a significant reduction of Cho/Cr
level in the ventral prefrontal white matter of MDD pa-
tients compared to that of controls. Cho is considered to
be a potential biomarker for the status of membrane
phospholipid metabolism [29]. Reduction of Cho levels
has been associated with decreased membrane turnover
and/or impaired intracellular signal transduction systems
[30,31]. Alternatively, as Cho is hugely present in glia
cells and myelin [32], the lower ratio of Cho/Cr may in-
dicate that abnormalities exist in membrane structure
and function of glial cells, and myelin. Previous morpho-
metric MRI has shown volumetric reductions in the ven-
tral prefrontal regions. Diffusion Tensor Imaging (DTI)
studies found decreased white matter integrity in differ-
ent white matter tracts in MDD [33]. Postmortem stud-
ies also reported lower density of oligodendroglial cells
in the prefrontal region of patients with MDD [34].
Taken together, our results suggest reduced bilateral
Cho/Cr in patients in the ventral prefrontal white matter
indicated that the prefrontal white matter may also play
a role in the pathophysiology of MDD. By thoroughly
reviewing the literature and meta-analysis results of the
1H-MRS on major depression through 2012, there was
no consistent evidence found that NAA and Cho are ei-
ther increased or decreased in patients with major depres-
sion. This appears to be evidence that brain chemistry
varies across different regions and thus warrants further
investigation.tment Cho/Cr level.
Table 2 Pre- and post-treatment comparison of patients’
Cho/Cr ratio in bilateral ventral prefrontal white matter
Left Cho/Cr Right Cho/Cr
Pre-treatment Post-treatment Pre-treatment Post-treatment
1 0.83 0.92 0.99 1.11
2 0.91 0.92 0.95 1.09
3 0.91 0.98 0.80 1.01
4 0.93 0.98 0.98 1.05
5 0.93 1.12 1.04 1.19
6 0.95 1.00 0.86 1.04
7 0.96 0.98 1.01 0.95
8 0.99 1.04 1.12 1.09
9 0.99 1.05 1.14 1.15
10 1.02 1.04 1.04 1.05
11 1.03 1.13 0.97 1.04
12 1.03 0.98 1.15 1.08
13 1.03 1.07 0.8 0.87
14 1.06 1.03 1.16 1.01
15 1.07 1.11 0.97 1.04
16 1.12 1.13 0.49 0.95
17 1.23 1.22 0.99 1.01
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Cho/Cr values in bilateral prefrontal white matter were sig-
nificantly increased compared to the pre-treatment values.
White matter structure consists mostly of glial cells and
myelinated axons that transmit signals from one region of
the cerebrum to another. Previous studies of SSRI treat-
ment had little focus on the role of glial cells. The glial cells
were only considered to actively participate neuronal net-
work activity. Their passive supportive role of neuronal
functions were mostly highlighted. Recent studies suggest
that glia cells are divided into three types, including
astrocytes, oligodendrocytes, and microglia [20,35]. As-
trocytes contribute to regulation of neurotransmission
through their processes wrapping around synapses and
to modulation of brain blood flow of the blood–brain-
barrier and brain blood flow through their end-feet sur-
rounding blood vessels. Oligodendrocytes are importantTable 3 Post-treatment MRS exam of patient group




NAA/Cr Cho/Cr NAA/Cr Cho/Cr
Pre-treatment 1.51 (0.17) 0.99 (0.09) 1.61 (0.16) 0.97 (0.11)
Post-treatment 1.51 (0.12) 1.05 (0.07) 1.60 (0.13) 1.04 (0.08)
t value 0.63 −3.13 0.266 −2.24
P value 0.53 0.006 0.79 0.04in forming the myelin sheaths around axons that guar-
antee conduction of electrical stimuli for long distances
without increasing axonal diameters. Microglia cells repre-
sent the resident CNS immune cells and are fundamental
surveyors of CNS extracellular environment that may help
the to maintain or restore homeostasis through pruning of
inappropriate synaptic contacts. Metabolic alterations of
frontal white matter after treatment with SSRIs in our
study may indicate a strong connection with this role in
the function of these glial cells.
The previous animal experiments found that anti-
depressant therapies acted on glial cells. Studies demon-
strated that mammalian myelin-forming cells require the
expression of some glia-specific proteins and genes to
maintain neuronal and axonal integrity [36-38]. There is
evidence that antidepressant treatments have a profound
stimulatory effect on the expression levels of various
trophic factors. It is also reported that antidepressant ac-
tions of SSRIs could modify astroglial physiology and
morphology by affecting gliogenesis. The antidepressants
may even regulate glial cell numbers [20,39]. The results
of animal experimental studies indicate that SSRIs may
not only affect neurons but also activate glial cells. How-
ever, the underlying molecular mechanisms are still un-
clear. Our results demonstrated that bilateral Cho/Cr of
patients in white matter were increased with SSRI treat-
ment and indicated that SSRIs might have a positive effect
on the regulation of glial cells and axons. Previous MRS
studies in depression reported abnormalities in the frontal
cortex, basal ganglia, hippocampus, anterior cingulate cor-
tex, and the occipital cortex. These abnormalities were im-
proved after treatment with selective serotonin reuptake
inhibitor, electroconvulsive therapy, and other antidepres-
sant therapy. These results indicated that antidepressant
treatment with its neurotrophic and neuroplasticity ef-
fects might play a positive role in restoring neuronal
and glial integrity.
Glial cells are active partners of neurons that regulate
the arrangement of neuronal circuits in specific brain re-
gions. Our results indicate that glial cells might be involved
with antidepressant action in restructuring neuronal and
glial integrity. The results of this study may be useful to
improve current treatment regimens or identify novel tar-
gets for the development of more efficacious antidepres-
sant drugs.
Conclusion
This study is the first one conducted to evaluate SSRI drug
response in the bilateral ventral prefrontal white matter in
patients with MDD using MRS technology. The results
suggest that alterations in ventral prefrontal white matter
metabolite levels are likely to be involved in MDD patho-
physiology and may help in understanding the pathophysi-
ology and the crucial role of white matter in MDD.
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